Last reviewed · How we verify
Sequential Lenvatinib
Sequential lenvatinib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) and fibroblast growth factor receptors (FGFR).
Sequential lenvatinib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) and fibroblast growth factor receptors (FGFR). Used for Metastatic renal cell carcinoma, Locally advanced or metastatic radiodermatitis.
At a glance
| Generic name | Sequential Lenvatinib |
|---|---|
| Also known as | Sequential targeted therapy |
| Sponsor | Sun Yat-sen University |
| Drug class | Tyrosine kinase inhibitor |
| Target | VEGFR, FGFR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting these receptors, lenvatinib reduces angiogenesis and tumor growth. This mechanism is particularly effective in treating various types of cancer.
Approved indications
- Metastatic renal cell carcinoma
- Locally advanced or metastatic radiodermatitis
Common side effects
- Hypertension
- Diarrhea
- Fatigue
- Nausea
- Weight loss
Key clinical trials
- HAIC Sequential TAE Combined With Lenvatinib and Tislelizumab in Unresectable HCC (PHASE2)
- The Efficacy of Sequential RT After Triple Therapy for uHCC
- Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma (EARLY_PHASE1)
- bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC (NA)
- Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC (PHASE3)
- Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)
- bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma (NA)
- TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sequential Lenvatinib CI brief — competitive landscape report
- Sequential Lenvatinib updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI